Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific

Edward L. Evans III, Jordan T. Becker, Stephanie L. Fricke, Kishan Patel, Nathan M. Sherer
Frank Kirchhoff, Editor
Edward L. Evans III
aMcArdle Laboratory for Cancer Research, Institute for Molecular Virology, & Carbone Cancer Center, University of Wisconsin—Madison, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordan T. Becker
aMcArdle Laboratory for Cancer Research, Institute for Molecular Virology, & Carbone Cancer Center, University of Wisconsin—Madison, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jordan T. Becker
Stephanie L. Fricke
aMcArdle Laboratory for Cancer Research, Institute for Molecular Virology, & Carbone Cancer Center, University of Wisconsin—Madison, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kishan Patel
aMcArdle Laboratory for Cancer Research, Institute for Molecular Virology, & Carbone Cancer Center, University of Wisconsin—Madison, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan M. Sherer
aMcArdle Laboratory for Cancer Research, Institute for Molecular Virology, & Carbone Cancer Center, University of Wisconsin—Madison, Madison, Wisconsin, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Kirchhoff
Ulm University Medical Center
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.02102-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Stable expression of mCcnt1-Y261C and hXPO1 is sufficient to rescue virus particle production in murine cells. (A) Western blot analysis comparing 3T3.CX cells that express mCcnt1 Y261C-3xHA and GFP-hXPO1 to permissive HeLa cells and the nonpermissive 3T3 parental control cell line. (B) Genomic layout of the NL4-3 strain HIV-1 reporter virus used in this study. In this virus, env and vpr genes are inactivated due to frameshift mutations, and the gene encoding red fluorescent protein mCherry was inserted into the nef locus, termed R-E-/mCherry. (C) HeLa, 3T3.CX, and 3T3 cells were infected with VSV-G-pseudotyped R-E-/mCherry virus at an MOI of ∼1 TU. Western blot analysis of supernatants and cell lysates harvested at 24-h time points as described in Materials and Methods. Gag species were detected using anti-p24Gag (CA) monoclonal antiserum and secondary antibodies conjugated to infrared fluorophores. Heat shock protein 90 (HSP90) was detected as a loading control. Peak rates of VLP production were observed between 24 and 48 hpi in HeLa cells (left), with peak rates of 3T3.CX cell production occurring later, at 48 to 72 hpi (middle). Little to no Gag/Gag-Pol expression was observed in parental 3T3 cells at any time point (right). (D) Fold differences in VLP p24Gag levels from panel C plotted over time, comparing infection of HeLa cells to that of 3T3.CX cells. Error bars represent the standard deviations from the means (n = 3); data show a representative example from three biological replicates. (E, F) mCherry expression was monitored using microscopy and quantified using a fluorescence spectrophotometer at 24-h time points. Bars, ∼100 μm. 3T3.CX cells exhibited robust mCherry expression after 72 hpi. Error bars represent the standard deviations from the means (n = 3); data show a representative example from three biological replicates. (G) Fluorescence microscopy of HeLa and 3T3.CX cells infected with R-E-/mCherry. Infected HeLa cells, but not 3T3.CX cells, exhibited extensive cell rounding at 72 hpi (arrows). Bars, ∼100 μm. (H) Still images from live-cell fluorescence microscopy of infected HeLa cells stained with a caspase 3/7 detection reagent (fluorescein isothiocyanate [FITC] channel). HeLa cells rounded at ∼30 hpi when infected with R-E-/mCherry and arrested for ∼10 to 20 h prior to undergoing apoptosis. In contrast, infected 3T3.CX cells were not observed to undergo cell rounding or apoptosis at any time point. The images in this panel can be seen in Movie S1.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    HIV-1 Vif causes CPE and G2/M cell cycle arrest in HeLa cells but not in 3T3.CX cells. HeLa and 3T3.CX cells were infected with either Vif+ or ΔVif R-E-/CFP viruses. (A) Visualization of infected HeLa and 3T3.CX cells. Bars, ∼100 μm. For all CFP images, all CFP fluorescence was pseudocolored black on a white background to maximize contrast. Accordingly, uninfected cells or infected cells expressing CFP at or below background are shown as white. Only HeLa cells infected with a Vif+ virus underwent cell rounding (insets), while HeLa cells infected with ΔVif viruses maintained normal cell morphology despite infection. 3T3.CX cells maintained normal cell morphology regardless of which virus (Vif+ or ΔVif) was used to infect cells. (B) Both HeLa and 3T3.CX cells were infected with Vif+ R-E-/CFP or ΔVif R-E-/CFP as indicated, harvested, and analyzed using flow cytometry to quantify per-cell DNA content using propidium iodide staining. For flow histograms, the leftmost peak indicates DNA content prior to S phase (G1), with the rightmost peak demonstrating cells with duplicated DNA content (G2/M). The blue curve between the G1 and G2/M peaks represents the S phase. Quantification of G2/M status for each condition is presented on the right of the flow histograms. Infecting HeLa cells with Vif+ viruses induced G2/M cell cycle arrest, while ΔVif virus did not, consistent with the observed cell morphology changes presented in panel A. 3T3.CX cells were nonresponsive to either virus and did not undergo G2/M cell cycle arrest. Error bars represent the standard deviations from the means (n = 3). (C) Treating HeLa or 3T3.CX cells with 1 μM nocodazole for 24 h induced potent G2/M cell cycle arrest and cell rounding changes in both cell lines (rightmost images). Error bars represent the standard deviations from the means (n = 3).

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Vif alone is sufficient to induce cell rounding and G2/M cell cycle arrest in HeLa cells but not in 3T3.CX cells. (A) Depiction of bicistronic retroviral vectors that express both codon-optimized Vif (CO-Vif) and cyan fluorescent protein (CFP) from reading frames separated by an internal ribosomal entry site (IRES). Three independent constructs were studied: CO-VifNL4-3 (induces G2/M arrest), C114S CO-VifNL4-3 (catalytically inactive, should not induce G2/M arrest), and CO-VifHXB2 (should not induce G2/M arrest). (B) Western blot analysis confirming that each construct expressed CO-Vif in addition to CFP, assayed in HeLa cells. (C) Visualization of HeLa cells and 3T3 cells transduced with each construct, separately. Bar, ∼100 μm. HeLa cells that expressed CO-VifNL4-3 underwent marked cell rounding (insets), while HeLa cells expressing C114S CO-VifNL4-3 and CO-VifHXB2 maintained normal cell morphology (compare mock [Vector] images to CO-Vif images). 3T3 cells, however, maintained normal cell morphology under every condition. Treatment with 1 μM nocodazole as a G2/M control induced cell rounding in both cell types. (D) Cell cycle analysis of HeLa and 3T3 cells using flow cytometry confirmed that 3T3 cells failed to undergo G2/M cell cycle arrest in the presence of CO-VifNL4-3 expression. Error bars represent the standard deviations from the means (n = 3).

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    Vif is capable of degrading hA3G, CBF-β, and PPP2R5D in both HeLa and 3T3 cells. (A) Model of the Vif-APOBEC3G E3 ubiquitin ligase complex based on that proposed by Letko et al. (95). In this model, Vif (cyan) is bound to elongin-C (orange), CBF-β (gray), and CUL5 (purple), with species-specific CUL5 residues near the Vif-binding interface highlighted in yellow. Elongin-B (red) is shown bound to elongin-C but does not bind to Vif directly. Amino acid sequences identifying mouse versus human orthologues of each factor are as indicated in the table. (B) HeLa and 3T3 cell lines stably expressing YFP-hA3G (yellow) were transduced to express increasing amounts of CO-VifNL4-3 as indicated. Images show YFP-hA3G degradation at 48 h postransduction, based on the disappearance of YFP fluorescence detected by microscopy using a 10× objective lens for ∼100 cells/field and measured using FIJI/ImageJ2 software. Bar, ∼100 μm. Insets show bright-field image of cells in order to illustrate the consistent cell density at 48 h. Note that YFP-hA3G is practically undetectable at the highest dose (800 μl) of Vif vector, consistent with efficient degradation. (C) Western blot analysis showing relative Vif, YFP-hA3G, CBFβ, and PPP2R5D levels for an experiment identical to that presented in panel B. HSP90 served as a negative control for Vif effects and also as a loading control. (D) Quantification of YFP-hA3G and PPP2R5D levels relative to HSP90 based on quantitative Western blotting (as shown in panel C) and confirming similar, dose-dependent degradation levels in either cell type. Error bars represent the standard deviations from the means (n = 3).

  • FIG 5
    • Open in new tab
    • Download powerpoint
    FIG 5

    Vif-induced cell cycle arrest is species specific. (A) Images of cell lines derived from humans (HeLa, HOS, U2OS) or a nonhuman primate (COS7) and infected with either Vif+ or ΔVif R-E-/mCherry HIV-1 and visualized using a 10× objective lens at 3 days postinfection. Bar, ∼100 μm. Inset images highlight frequent observations of cell rounding and cytopathic effect. (B) Additional informative nonhuman cell lines derived from rodent (mouse L cells, Rat1, Chinese hamster ovary [CHO]), chiropteran (TB1), and avian (DF1) species and infected with Vif+ and ΔVif viruses as indicated. Images were collected as described for panel A and are shown for a later time point, 7 days postinfection, to demonstrate that infection by either virus was tolerated for all cell types relative to the HeLa cell control. Bar, ∼100 μm. Inset images highlight the few remaining HeLa cells in culture at 7 days postinfection with the Vif+ virus. (C) Quantification of mCherry mean fluorescence intensity (MFI) for whole-field imaging of the cells presented in panel A, demonstrating the loss of mCherry-expressing human cells at 6 days postinfection. Error bars represent the standard deviations from the means for three independent infections. For both panels C and D, the skull and crossbone symbols indicate high levels of cell death (as opposed to reductions to per-cell mCherry fluorescence). (D) Plot of mCherry MFI, as described for panel C, for whole-field imaging of the cells at 7 days postinfection presented in panel B. (E) Western blot analysis for cell lysates as described for Fig. 1E depicting Gag/Gag-Pol expression and cleavage profiles for HeLa and Cos7 cells infected with the indicated viruses and harvested at 6 days postinfection. Equivalent amounts of total protein were loaded into each well, thus confirming that Cos7 cells can tolerate and maintain infection with a Vif+ virus over multiple cell divisions, while infected HeLa cells are gradually lost from the culture. (F) Cell cycle analysis as described for Fig. 3, comparing HeLa and Cos7 cells transduced to express CO-VifNL4-3 in the absence of other viral factors. Notably, Cos7 cells were largely resistant to HIV-1 Vif-mediated G2/M cell cycle arrest. Error bars represent the standard deviations from the means (n = 3).

  • FIG 6
    • Open in new tab
    • Download powerpoint
    FIG 6

    Proposed models for mouse cell resistance of HIV-1 Vif-mediated G2/M cell cycle arrest. We present two working models for Vif-mediated G2/M cell cycle arrest. (A) Vif is able to identify and ultimately degrade a yet-to-be identified substrate that regulates G2/M arrest in human cells. In mouse cells, this substrate either is lacking or does not interact with Vif. (B) In human cells, the recently identified PP2A subunit substrates are degraded by Vif to induce G2/M arrest, perhaps through modulation of aurora kinase activity, as proposed by Greenwood et al. (47). Vif can degrade PP2A subunits in mouse cells (Fig. 4), but this mechanism may be uncoupled from a downstream, human-specific regulatory factor.

Additional Files

  • Figures
  • Supplemental material

    • Supplemental file 1 -

      Movie S1 (Live-cell imaging of infected HeLa and 3T3.CX cells.)

      AVI, 12M

    • Supplemental file 2 -

      Supplemental Movie Legend.

      PDF, 16K

    • Supplemental file 3 -

      Fig. S1 (DNA alignment of native Vif sequences to codon-optimized sequences.)

      PDF, 306K

PreviousNext
Back to top
Download PDF
Citation Tools
HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific
Edward L. Evans III, Jordan T. Becker, Stephanie L. Fricke, Kishan Patel, Nathan M. Sherer
Journal of Virology Mar 2018, 92 (7) e02102-17; DOI: 10.1128/JVI.02102-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific
Edward L. Evans III, Jordan T. Becker, Stephanie L. Fricke, Kishan Patel, Nathan M. Sherer
Journal of Virology Mar 2018, 92 (7) e02102-17; DOI: 10.1128/JVI.02102-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

APOBEC3G
cyclin T1
exportin-1
G2/M
PPP2R5D
Rev
Vif
cell cycle
HIV
species specific

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514